# A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR201 in the Treatment of Subjects With Parkinson's Disease

> **NCT06978920** · PHASE1 · RECRUITING · sponsor: **Nuwacell Biotechnologies Co., Ltd.** · enrollment: 48 (estimated)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Allogeneic dopaminergic neural precursor cell(NCR201)

## Key facts

- **NCT ID:** NCT06978920
- **Lead sponsor:** Nuwacell Biotechnologies Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-06
- **Primary completion:** 2026-07-01
- **Final completion:** 2028-12-01
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06978920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06978920, "A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR201 in the Treatment of Subjects With Parkinson's Disease". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06978920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*